The strategic approach taken by CardieX to own cardiovascular...

The strategic approach taken by CardieX to own cardiovascular biomarkers, working that into AHA guidelines, as per the highlighted sentence below, has just received an enormous shot in the arm with a new American Heart Association presidential advisory released today.

The advisory identifies the strong connections among cardiovascular disease (CVD), kidney disease, Type 2 diabetes and obesity, and suggests redefining CVD risk, prevention and management.The advisory defines cardiovascular-kidney-metabolic (CKM) syndrome for the first time.

https://newsroom.heart.org/news/heart-disease-risk-prevention-and-management-redefined

From the CDX release.

We are also firmly focusing our efforts on the industry standards bodies such as A4M and the American Heart Association (“AHA”) with the goal of bringing our SphygmoCor technology into the AHA guidelines for the management of cardiovascular disease.


Highlighting aspects of the AHA release, that was released a few hours ago.

According to the American Heart Association’s 2023 Statistical Update, 1 in 3 U.S. adults have three or more risk factors that contribute to cardiovascular disease, metabolic disorders and/or kidney disease. CKM affects nearly every major organ in the body, including the heart, brain, kidney and liver. However, the biggest impact is on the cardiovascular system, affecting blood vessels and heart muscle function, the rate of fatty buildup in arteries, electrical impulses in the heart and more.

“The advisory addresses the connections among these conditions with a particular focus on identifying people at early stages of CKM syndrome,” said Chiadi E. Ndumele, M.D., Ph.D., M.H.S., FAHA, writing committee chair and an associate professor of medicine and director of obesity and cardiometabolic research in the division of cardiology at Johns Hopkins University in Baltimore. “Screening for kidney and metabolic disease will help us start protective therapies earlier to most effectively prevent heart disease and best manage existing heart disease.”

CKM screening, stages and treatment

CKM-related screening is intended to detect cardiovascular, metabolic and kidney health changes early; identify social and structural barriers to care; and prevent progression to the next stage of CKM syndrome.

Calls to Action

The advisory calls for systemic changes to optimize CKM health.“There is a need for fundamental changes in how we educate health care professionals and the public, how we organize care and how we reimburse care related to CKM syndrome,” Ndumele said. “Key partnerships among stakeholders are needed to improve access to therapies, to support new care models and to make it easier for people from diverse communities and circumstances to live healthier lifestyles and to achieve ideal cardiovascular health.”